Optimization of Prostate Biopsy Referral Decisions
暂无分享,去创建一个
Brian T. Denton | Jingyu Zhang | Hari Balasubramanian | Nilay D. Shah | Brant A. Inman | N. Shah | B. Denton | H. Balasubramanian | B. Inman | Jingyu Zhang | N. Shah
[1] J. Crowley,et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. , 2004, The New England journal of medicine.
[2] Peter H Gann,et al. Prostate specific antigen best practice statement: 2009 update. , 2009, The Journal of urology.
[3] M Bolla,et al. EAU guidelines on prostate cancer. , 2001, European urology.
[4] S. Loeb,et al. AN EXAMINATION OF THE DYNAMIC CHANGES IN PROSTATE‐SPECIFIC ANTIGEN OCCURRING IN A POPULATION‐BASED COHORT OF MEN OVER TIME , 2012, BJU international.
[5] Ariela Sofer,et al. Optimal Biopsy Protocols for Prostate Cancer , 2003, Ann. Oper. Res..
[6] Hau L. Lee,et al. Mass Screening Models for Contagious Diseases with No Latent Period , 1988, Oper. Res..
[7] M. Roobol,et al. Interval cancers in prostate cancer screening: comparing 2- and 4-year screening intervals in the European Randomized Study of Screening for Prostate Cancer, Gothenburg and Rotterdam. , 2007, Journal of the National Cancer Institute.
[8] Martin L. Puterman,et al. Markov Decision Processes: Discrete Stochastic Dynamic Programming , 1994 .
[9] V. Moyer,et al. Screening for Prostate Cancer: U.S. Preventive Services Task Force Recommendation Statement , 2012, Annals of Internal Medicine.
[10] William J Catalona,et al. Effect of verification bias on screening for prostate cancer by measurement of prostate-specific antigen. , 2003, The New England journal of medicine.
[11] H. Welch,et al. Overdiagnosis in cancer. , 2010, Journal of the National Cancer Institute.
[12] Matthew T Gettman,et al. Reassessing the diagnostic yield of saturation biopsy of the prostate. , 2008, European urology.
[13] A. Finelli,et al. Cost‐effectiveness analysis of immediate radical cystectomy versus intravesical Bacillus Calmette‐Guerin therapy for high‐risk, high‐grade (T1G3) bladder cancer , 2009, Cancer.
[14] Monique J. Roobol,et al. Mortality Results from a Randomized ProstateCancer Screening Trial , 2009 .
[15] C. Lawton,et al. Screening and Prostate-Cancer Mortality in a Randomized European Study , 2010 .
[16] Oguzhan Alagoz,et al. A Clinically Based Discrete-Event Simulation of End-Stage Liver Disease and the Organ Allocation Process , 2005, Medical decision making : an international journal of the Society for Medical Decision Making.
[17] Seth Falcon,et al. Impact of PSA Screening on the Incidence of Advanced Stage Prostate Cancer in the United States: A Surveillance Modeling Approach , 2008, Medical decision making : an international journal of the Society for Medical Decision Making.
[18] Daniel O Scharfstein,et al. Utility of saturation biopsy to predict insignificant cancer at radical prostatectomy. , 2005, Urology.
[19] U. G. Dailey. Cancer,Facts and Figures about. , 2022, Journal of the National Medical Association.
[20] Pär Stattin,et al. Prostate specific antigen for early detection of prostate cancer: longitudinal study , 2009, BMJ : British Medical Journal.
[21] James Waterman Glover. United States Life Tables , 2013 .
[22] Andrew J. Schaefer,et al. The Optimal Timing of Living-Donor Liver Transplantation , 2004, Manag. Sci..
[23] Edward J. Sondik,et al. The Optimal Control of Partially Observable Markov Processes over a Finite Horizon , 1973, Oper. Res..
[24] Steven L. Shafer,et al. Comparison of Some Suboptimal Control Policies in Medical Drug Therapy , 1996, Oper. Res..
[25] J. W. Bush,et al. A Health-Status Index and its Application to Health-Services Outcomes , 1970, Oper. Res..
[26] D. Fryback,et al. HALYS and QALYS and DALYS, Oh My: similarities and differences in summary measures of population Health. , 2002, Annual review of public health.
[27] R. J. Gallagher,et al. Treatment planning for brachytherapy: an integer programming model, two computational approaches and experiments with permanent prostate implant planning. , 1999, Physics in medicine and biology.
[28] G. Monahan. State of the Art—A Survey of Partially Observable Markov Decision Processes: Theory, Models, and Algorithms , 1982 .
[29] Lawrence M. Wein,et al. Pooled Testing for HIV Screening: Capturing the Dilution Effect , 2018, Oper. Res..
[30] Peter H Gann,et al. Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. , 2002, Journal of the National Cancer Institute.
[31] Stephen M Downs,et al. The Role of Parental Preferences in the Management of Fever Without Source Among 3- to 36-Month-Old Children: A Decision Analysis , 2006, Pediatrics.
[32] D. E. Neal,et al. CONSERVATIVE MANAGEMENT OF PROSTATE CANCER , 1988, The Lancet.
[33] S. Christian Albright,et al. Structural Results for Partially Observable Markov Decision Processes , 1979, Oper. Res..
[34] Michel Bolla,et al. [EAU guidelines on prostate cancer]. , 2009, Actas urologicas espanolas.
[35] Alan W Partin,et al. Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000 to 2005. , 2007, Urology.
[36] Edward J. Sondik,et al. The optimal control of par-tially observable Markov processes , 1971 .
[37] Anthony V D'Amico,et al. Decision analysis using individual patient preferences to determine optimal treatment for localized prostate cancer , 2007, Cancer.
[38] Andrew J Vickers,et al. An empirical evaluation of guidelines on prostate-specific antigen velocity in prostate cancer detection. , 2011, Journal of the National Cancer Institute.
[39] R A Greenes,et al. Assessment of diagnostic tests when disease verification is subject to selection bias. , 1983, Biometrics.
[40] B. Kinosian,et al. Strategies for screening blood for human immunodeficiency virus antibody. Use of a decision support system. , 1990, JAMA.
[41] Milos Hauskrecht,et al. Planning treatment of ischemic heart disease with partially observable Markov decision processes , 2000, Artif. Intell. Medicine.
[42] H. Moch,et al. Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. , 2000, Human pathology.
[43] Karl Johan Åström,et al. Optimal control of Markov processes with incomplete state information , 1965 .
[44] Arnold H. Packer,et al. Applying Cost-Effectiveness Concepts to the Community Health System , 1968, Oper. Res..
[45] Antoinette M Stroup,et al. Prostate cancer early detection , 2010 .
[46] David Robinson,et al. Survival in prostate carcinoma—Outcomes from a prospective, population‐based cohort of 8887 men with up to 15 years of follow‐up , 2005, Cancer.
[47] Markus Graefen,et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer - A multi-institutional update , 2004, Aktuelle Urologie.
[48] Amit Patel,et al. Prostate cancer detection with office based saturation biopsy in a repeat biopsy population. , 2004, The Journal of urology.
[49] Alan W Partin,et al. Characteristics of insignificant clinical T1c prostate tumors , 2004, Cancer.
[50] Ashesh B Jani,et al. Influence of demographic factors on outcome of collecting duct carcinoma: a Surveillance, Epidemiology, and End Results (SEER) database analysis. , 2009, Clinical genitourinary cancer.
[51] Peter C Albertsen,et al. Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005. , 2009, Journal of the National Cancer Institute.
[52] Wenju Liu,et al. Planning in Stochastic Domains: Problem Characteristics and Approximation , 1996 .
[53] S. Woolf,et al. Screening for prostate cancer: the roles of science, policy, and opinion in determining what is best for patients. , 1999, Annual review of medicine.
[54] J. Oesterling,et al. Ejaculation increases the serum prostate-specific antigen concentration. , 1996, Urology.
[55] J. McNeal,et al. Use of extended systematic sampling in patients with a prior negative prostate needle biopsy. , 2002, The Journal of urology.
[56] Jonathan H Sunshine,et al. Comparing the costs of radiation therapy and radical prostatectomy for the initial treatment of early-stage prostate cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[57] K. Grigor,et al. Trends in reporting Gleason score 1991 to 2001: changes in the pathologist's practice. , 2005, European urology.
[58] Oguzhan Alagöz,et al. Optimal Breast Biopsy Decision-Making Based on Mammographic Features and Demographic Factors , 2010, Oper. Res..
[59] P Carlsson,et al. A population-based study of pain and quality of life during the year before death in men with prostate cancer , 2004, British Journal of Cancer.
[60] Jorge Yao,et al. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. , 2006, The Lancet. Oncology.
[61] Robert A Smith,et al. American Cancer Society guidelines for the early detection of cancer , 2000, CA: a cancer journal for clinicians.
[62] Peter B. Schiff,et al. Surveillance Epidemiology and End Results (SEER) analysis confirms overall survival benefit with concurrent chemoradiotherapy for cervical cancer , 2013 .
[63] Karen E Bremner,et al. A Review and Meta-Analysis of Prostate Cancer Utilities , 2007, Medical decision making : an international journal of the Society for Medical Decision Making.
[64] Ross D. Shachter,et al. A Bayesian Network to Assist Mammography Interpretation , 2005 .
[65] C. White. Monotone control laws for noisy, countable-state Markov chains , 1980 .
[66] Lisa M. Maillart,et al. Assessing Dynamic Breast Cancer Screening Policies , 2008, Oper. Res..
[67] R. Thomson,et al. Decision aids for people facing health treatment or screening decisions. , 2003, The Cochrane database of systematic reviews.
[68] D. Penson,et al. Trends in the treatment of localized prostate cancer using supplemented cancer registry data , 2011, BJU international.
[69] T. H. van der Kwast,et al. Interval carcinomas in the European Randomized Study of Screening for Prostate Cancer (ERSPC)-Rotterdam. , 2003, Journal of the National Cancer Institute.
[70] M C Weinstein,et al. Gains in life expectancy from medical interventions--standardizing data on outcomes. , 1998, The New England journal of medicine.
[71] L. Holmberg,et al. Prostate-specific antigen levels as a predictor of lethal prostate cancer. , 2007, Journal of the National Cancer Institute.
[72] Nicolas Barry Delongchamps,et al. Needle biopsies on autopsy prostates: sensitivity of cancer detection based on true prevalence. , 2007, Journal of the National Cancer Institute.
[73] David Chia,et al. Mortality results from a randomized prostate-cancer screening trial. , 2009, The New England journal of medicine.
[74] H A Guess,et al. Comparative efficiency of prostate-specific antigen screening strategies for prostate cancer detection. , 2000, JAMA.
[75] Douglas K Owens,et al. Screening Women of Childbearing Age for Human Immunodeficiency Virus: A Model-Based Policy Analysis , 1993 .
[76] Michael W Kattan,et al. Performance of prostate cancer prevention trial risk calculator in a contemporary cohort screened for prostate cancer and diagnosed by extended prostate biopsy. , 2010, The Journal of urology.
[77] William S. Lovejoy,et al. Some Monotonicity Results for Partially Observed Markov Decision Processes , 1987, Oper. Res..
[78] Ziding Feng,et al. Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. , 2006, Journal of the National Cancer Institute.
[79] T. Wilt,et al. Screening for prostate cancer. , 2013, The Cochrane database of systematic reviews.
[80] Murray Krahn,et al. Patient and Community Preferences for Outcomes in Prostate Cancer: Implications for Clinical Policy , 2003, Medical care.
[81] Patrick C. Walsh,et al. American Cancer Society guidelines for the early detection of cancer. , 2002, CA: a cancer journal for clinicians.
[82] Antoinette M Stroup,et al. NCCN clinical practice guidelines in oncology: prostate cancer early detection. , 2010, Journal of the National Comprehensive Cancer Network : JNCCN.
[83] Edward J. Sondik,et al. The Optimal Control of Partially Observable Markov Processes over the Infinite Horizon: Discounted Costs , 1978, Oper. Res..
[84] E. Arias,et al. United States life tables, 2006. , 2010, National vital statistics reports : from the Centers for Disease Control and Prevention, National Center for Health Statistics, National Vital Statistics System.
[85] W. Catalona,et al. Effect of ejaculation on serum total and free prostate-specific antigen concentrations. , 1997, Urology.
[86] Michael L. Littman,et al. Incremental Pruning: A Simple, Fast, Exact Method for Partially Observable Markov Decision Processes , 1997, UAI.
[87] Viraj A Master,et al. The independent impact of extended pattern biopsy on prostate cancer stage migration. , 2005, The Journal of urology.
[88] Michael J Barry,et al. Screening for prostate cancer--the controversy that refuses to die. , 2009, The New England journal of medicine.
[89] Nilay D Shah,et al. Optimizing the Start Time of Statin Therapy for Patients with Diabetes , 2009, Medical decision making : an international journal of the Society for Medical Decision Making.
[90] George E. Monahan,et al. A Survey of Partially Observable Markov Decision Processes: Theory, Models, and Algorithms , 2007 .